Catalyst Pharmaceuticals Inc (CPRX)
16.72
+0.32
(+1.95%)
USD |
NASDAQ |
May 17, 12:26
Catalyst Pharmaceuticals Price to Book Value: 3.518 for May 17, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 3.450 |
| May 15, 2024 | 3.505 |
| May 14, 2024 | 3.469 |
| May 13, 2024 | 3.412 |
| May 10, 2024 | 3.354 |
| May 09, 2024 | 3.293 |
| May 08, 2024 | 3.097 |
| May 07, 2024 | 3.185 |
| May 06, 2024 | 3.154 |
| May 03, 2024 | 3.095 |
| May 02, 2024 | 3.158 |
| May 01, 2024 | 3.196 |
| April 30, 2024 | 3.164 |
| April 29, 2024 | 3.202 |
| April 26, 2024 | 3.130 |
| April 25, 2024 | 3.086 |
| April 24, 2024 | 3.179 |
| April 23, 2024 | 3.097 |
| April 22, 2024 | 3.175 |
| April 19, 2024 | 3.181 |
| April 18, 2024 | 3.225 |
| April 17, 2024 | 3.364 |
| April 16, 2024 | 3.267 |
| April 15, 2024 | 3.236 |
| April 12, 2024 | 3.200 |
| Date | Value |
|---|---|
| April 11, 2024 | 3.324 |
| April 10, 2024 | 3.339 |
| April 09, 2024 | 3.320 |
| April 08, 2024 | 3.261 |
| April 05, 2024 | 3.189 |
| April 04, 2024 | 3.179 |
| April 03, 2024 | 3.257 |
| April 02, 2024 | 3.208 |
| April 01, 2024 | 3.309 |
| March 31, 2024 | |
| March 28, 2024 | 4.850 |
| March 27, 2024 | 4.944 |
| March 26, 2024 | 4.786 |
| March 25, 2024 | 4.819 |
| March 22, 2024 | 4.780 |
| March 21, 2024 | 5.050 |
| March 20, 2024 | 5.138 |
| March 19, 2024 | 4.980 |
| March 18, 2024 | 4.886 |
| March 15, 2024 | 4.883 |
| March 14, 2024 | 4.920 |
| March 13, 2024 | 5.050 |
| March 12, 2024 | 4.923 |
| March 11, 2024 | 4.892 |
| March 08, 2024 | 4.938 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.965
Minimum
Sep 30 2020
12.09
Maximum
Sep 11 2019
4.397
Average
3.991
Median
Price to Book Value Benchmarks
| Pfizer Inc | 1.756 |
| Sarepta Therapeutics Inc | 12.86 |
| PTC Therapeutics Inc | -- |
| Corcept Therapeutics Inc | 5.348 |
| Cytokinetics Inc | -- |
Price to Book Value Related Metrics
| PE Ratio | 30.96 |
| PS Ratio | 4.648 |
| Price to Free Cash Flow | 23.43 |
| Price | 16.72 |
| Earnings Yield | 3.23% |
| Market Cap | 1.975B |
| Operating PE Ratio | 24.41 |
| Normalized PE Ratio | 30.96 |